PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23530020-11 2013 Collectively, we found that the metabolites produced by human CES-, CYP2E1-, and CYP3A4-mediated metabolism were involved in prilocaine- and lidocaine-induced methemoglobinemia. Lidocaine 141-150 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 16894333-8 2006 CONCLUSION: HT can influence the pharmacokinetics of lidocaine, ie, its hepatic metabolism, through CYP3A4 and CYP1A2. Lidocaine 53-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 100-106 18846481-8 2008 HepG2-GS-3A4 selectively metabolized substrates of CYP3A4 (diazepam, nordiazepam, lidocaine, atorvastatin, and nifedipine) to a greater degree than control. Lidocaine 82-91 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-57 23530020-0 2013 Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. Lidocaine 16-25 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-109 18679666-8 2008 CONCLUSION: The present data permit us to conclude that the apparent clearance of lidocaine and MEGX was reduced in diabetic patients compared to normal women, suggesting that GDM inhibits the CYP1A2/CYP3A4 isoforms responsible for the metabolism of this drug and its metabolite. Lidocaine 82-91 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 200-206 16435566-3 2005 Lidocaine is frequently used in the treatment of hemodynamic changes following laryngoscopy and tracheal intubation during general anesthesia, and is metabolized by CYP3A4 and CYP1A2 isoenzymes in the liver. Lidocaine 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 165-171 16918719-1 2006 Lidocaine is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, but inhibitors of CYP3A4 have had only a minor effect on its pharmacokinetics. Lidocaine 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-47 16918719-1 2006 Lidocaine is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, but inhibitors of CYP3A4 have had only a minor effect on its pharmacokinetics. Lidocaine 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-55 16918719-1 2006 Lidocaine is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, but inhibitors of CYP3A4 have had only a minor effect on its pharmacokinetics. Lidocaine 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 95-101 16918719-2 2006 We studied the effect of co-administration of fluvoxamine (CYP1A2 inhibitor) and erythromycin (CYP3A4 inhibitor) on the pharmacokinetics of lidocaine in a double-blind, randomized, three-way cross-over study. Lidocaine 140-149 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 95-101 16918719-11 2006 The concomitant use of both fluvoxamine and a CYP3A4 inhibitor like erythromycin may further increase plasma lidocaine concentrations. Lidocaine 109-118 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 46-52 14715049-15 2004 The main CYP isoforms involved are CYP3A4 for lidocaine and bupivacaine and CYP1A2 for ropivacaine. Lidocaine 46-55 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-41 15845683-9 2005 Concomitant use of both fluvoxamine and a CYP3A4 inhibitor such as erythromycin can further increase plasma lidocaine concentrations by decreasing its clearance. Lidocaine 108-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 42-48 15845683-1 2005 Inhibitors of CYP3A4 (cytochrome P450 3A4) have a minor effect on lidocaine pharmacokinetics. Lidocaine 66-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20 15845683-1 2005 Inhibitors of CYP3A4 (cytochrome P450 3A4) have a minor effect on lidocaine pharmacokinetics. Lidocaine 66-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-41 15845683-2 2005 We studied the effect of coadministration of the antidepressant fluvoxamine (CYP1A2 inhibitor) and antimicrobial drug erythromycin (CYP3A4 inhibitor) on lidocaine pharmacokinetics in a double-blind, randomized, three-way crossover study. Lidocaine 153-162 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 132-138 15383492-5 2004 Based on this parameter, CYP3A5 was more active than CYP3A4 in catalyzing total midazolam hydroxylation (3-fold) and lidocaine demethylation (1.4-fold). Lidocaine 117-126 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 15447735-1 2004 Lidocaine is metabolized by cytochrome P450 3A4 and 1A2 enzymes (CYP3A4 and CYP1A2) in vitro. Lidocaine 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-55 15447735-1 2004 Lidocaine is metabolized by cytochrome P450 3A4 and 1A2 enzymes (CYP3A4 and CYP1A2) in vitro. Lidocaine 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 15447735-3 2004 We have studied the effect of a potent CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of inhaled lidocaine in ten healthy volunteers using a randomized, two-phase cross-over study design. Lidocaine 106-115 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 39-45 10608481-1 1999 CYP3A4 is generally believed to be the major CYP enzyme involved in the biotransformation of lidocaine in man; however, recent in vivo studies suggest that this may not be the case. Lidocaine 93-102 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 12708606-0 2003 The effect of propofol (anesthetic and inhibitor of CYP3A4) on serum lidocaine concentrations in smokers and chronic alcohol consumers. Lidocaine 69-78 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-58 10786743-4 2000 CYP3A4 is responsible for the metabolism of numerous other therapeutic agents, including those administered concurrently with fentanyl (e.g., nifedipine, lidocaine, erythromycin and cyclosporine). Lidocaine 154-163 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 12534644-0 2003 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Lidocaine 71-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20 12483453-6 2002 A lidocaine (L) test was carried out as an in vivo marker of CYP3A4 (and CYP1A2) activities. Lidocaine 2-11 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 61-67 10901707-4 2000 Troleandomycin inhibited the N-deethylation of lidocaine by about 50% at 800 microM lidocaine, suggesting that the role of CYP3A4 may be more important than that of CYP1A2 at high lidocaine concentrations. Lidocaine 47-56 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 123-129 10608481-10 1999 Although further studies are needed to elucidate the role of distinct CYP enzymes in the biotransformation of lidocaine in humans, the findings of this study suggest that while both CYP1A2 and CYP3A4 are involved in the metabolism of lidocaine by human liver microsomes, CYP1A2 is the more important isoform at clinically relevant lidocaine concentrations. Lidocaine 110-119 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 193-199 10608481-10 1999 Although further studies are needed to elucidate the role of distinct CYP enzymes in the biotransformation of lidocaine in humans, the findings of this study suggest that while both CYP1A2 and CYP3A4 are involved in the metabolism of lidocaine by human liver microsomes, CYP1A2 is the more important isoform at clinically relevant lidocaine concentrations. Lidocaine 234-243 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 193-199 10608481-10 1999 Although further studies are needed to elucidate the role of distinct CYP enzymes in the biotransformation of lidocaine in humans, the findings of this study suggest that while both CYP1A2 and CYP3A4 are involved in the metabolism of lidocaine by human liver microsomes, CYP1A2 is the more important isoform at clinically relevant lidocaine concentrations. Lidocaine 234-243 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 193-199 8891878-12 1996 The interaction between amiodarone and lidocaine may be explained by the inhibition of CYP3A4 by amiodarone and/or by its main metabolite DEA. Lidocaine 39-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 87-93 10193676-1 1999 Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%. Lidocaine 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-55 10193676-1 1999 Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%. Lidocaine 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 57-63 9862241-1 1998 AIMS: The N-deethylation of lignocaine to monoethylglycinexylidide (MEGX) is partially catalysed by the rifampicin inducible P-450 isoenzyme CYP3A4. Lidocaine 28-38 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 141-147 9862241-3 1998 lignocaine) as a marker of CYP3A4 activity. Lidocaine 0-10 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 9832299-1 1998 OBJECTIVE: We have studied the possible interaction of erythromycin and itraconazole, both inhibitors of cytochrome P450 3A4 isoenzyme (CYP3A4), with intravenous lignocaine in nine healthy volunteers using a randomized cross-over study design. Lidocaine 162-172 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 136-142 9143866-6 1997 Quinidine and lignocaine, although they are substrates of CYP3A, showed preferential inhibition over the O-demethylation of codeine, suggesting a low affinity to the CYP3A. Lidocaine 14-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-63 9143866-6 1997 Quinidine and lignocaine, although they are substrates of CYP3A, showed preferential inhibition over the O-demethylation of codeine, suggesting a low affinity to the CYP3A. Lidocaine 14-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 166-171 10193676-2 1999 We have studied the possible effect of two inhibitors of CYP3A4, erythromycin and itraconazole, on the pharmacokinetics of oral lignocaine in nine volunteers using a cross-over study design. Lidocaine 128-138 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 57-63 10193676-9 1999 The extent of the interaction of lignocaine with these CYP3A4 inhibitors was, however, less than that of, e.g. midazolam or buspirone, and it did not correlate with the CYP3A4 inhibiting potency of erythromycin and itraconazole. Lidocaine 33-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 9298257-11 1997 To demonstrate that the rifampin-induction of testosterone 6 beta-hydroxylation could be generalized to other CYP3A4 substrates, we evaluated the metabolism of another known substrate of CYP3A4, lidocaine. Lidocaine 195-204 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 187-193 8953808-0 1996 Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. Lidocaine 65-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 8-14 8033500-5 1994 Our results show that, in patients with porphyria and in healthy subjects, exogenous heme is able to accelerate the reactions mediated by the cytochrome isozymes CYP2D6 (debrisoquin) and CYP3A4 (lidocaine) but not reactions mediated by CYP1A2 (caffeine) and CYP2A6 (coumarin). Lidocaine 195-204 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 187-193 7636727-3 1995 Rifampicin has been shown to induce CYP3A4, a major human hepatic CYP isozyme that is known to metabolize lidocaine to its primary metabolite, monoethylglycinexylidide. Lidocaine 106-115 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 7756103-0 1995 CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Lidocaine 57-67 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 7756103-2 1995 The in vitro hepatic metabolism of lignocaine to monoethylglycinexylide (MEGX) is mediated by CYP3A4 and that of coumarin to 7-hydroxycoumarin (7OHC) by CYP2A6. Lidocaine 35-45 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 94-100 1642641-2 1992 The clearance of quinidine, midazolam, triazolam, erythromycin, and lidocaine declines with age; these drugs are metabolized by the isoform, CYP3A. Lidocaine 68-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 141-146 29263648-0 2017 Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Lidocaine 52-61 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-31 29263648-4 2017 The aim of this study was to systematically investigate the genetic polymorphisms of 23 CYP3A4 alleles and evaluate their catalytic activities on the metabolism of lidocaine in vitro. Lidocaine 164-173 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 29263648-6 2017 Then the insect microsomes were incubated with the CYP3A4-specific substrate lidocaine. Lidocaine 77-86 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-57 29263648-9 2017 Conclusion: As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. Lidocaine 63-72 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 29263648-9 2017 Conclusion: As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. Lidocaine 63-72 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 204-210 29263648-9 2017 Conclusion: As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. Lidocaine 275-284 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 29263648-9 2017 Conclusion: As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting. Lidocaine 275-284 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 204-210